OBJECTIVE: To evaluate if placental histopathological changes of vascular insufficiency correlate with circulating angiogenic factors in patients with preeclampsia. MATERIALS AND METHODS: Subjects were selected from a previous prospective cohort study of preeclampsia based on the availability of plasma anti-angiogenic factor (sFlt1) and pro-angiogenic factor (PlGF) measurements and placental histology specimens. Preeclamptic patients were divided into two groups based on plasma levels of these factors described as a ratio: anti-angiogenic preeclampsia with sFlt1/PlGF ratio ≥85 and normal angiogenic preeclampsia with sFlt1/PlGF < 85. The placental lesions of vascular insufficiency that were studied specifically included atherosis, infarcts, syncytial knots, acute and chronic abruption, hematoma, and fetal thrombosis. The data are shown as median (quartile 1 and quartile 3) or n (%) when appropriate. RESULTS: The anti-angiogenic preeclampsia group (N = 48) presented at an earlier gestational age (weeks) than the normal angiogenic group (N = 28); {32 (28, 34) versus 35 (32, 36), p = 0.002}, had higher systolic blood pressure (mmHg) {154 (147, 168) versus 147 (132, 158), p = 0.02}, delivered early (weeks) {(32 (29, 34) versus 36 (34, 37), p < 0.001} and had lower birth weight (grams) {(1550 (1055, 2060) versus 2655 (2285, 3343), p < 0.001}. Several pathologic lesions were found significantly more often in the anti-angiogenic preeclampsia group; atherosis {27.7% versus 3.6%, p < 0.05}, infarcts {58.3% versus 3.6%, p = 0.002}, and syncytial knots {81.3% versus 39.3%, p < 0.001}. CONCLUSION: Preeclamptic patients with imbalance in circulating angiogenic factors have disproportionally higher rates of placental vascular lesions historically associated with severe disease.
OBJECTIVE: To evaluate if placental histopathological changes of vascular insufficiency correlate with circulating angiogenic factors in patients with preeclampsia. MATERIALS AND METHODS: Subjects were selected from a previous prospective cohort study of preeclampsia based on the availability of plasma anti-angiogenic factor (sFlt1) and pro-angiogenic factor (PlGF) measurements and placental histology specimens. Preeclamptic patients were divided into two groups based on plasma levels of these factors described as a ratio: anti-angiogenic preeclampsia with sFlt1/PlGF ratio ≥85 and normal angiogenic preeclampsia with sFlt1/PlGF < 85. The placental lesions of vascular insufficiency that were studied specifically included atherosis, infarcts, syncytial knots, acute and chronic abruption, hematoma, and fetal thrombosis. The data are shown as median (quartile 1 and quartile 3) or n (%) when appropriate. RESULTS: The anti-angiogenic preeclampsia group (N = 48) presented at an earlier gestational age (weeks) than the normal angiogenic group (N = 28); {32 (28, 34) versus 35 (32, 36), p = 0.002}, had higher systolic blood pressure (mmHg) {154 (147, 168) versus 147 (132, 158), p = 0.02}, delivered early (weeks) {(32 (29, 34) versus 36 (34, 37), p < 0.001} and had lower birth weight (grams) {(1550 (1055, 2060) versus 2655 (2285, 3343), p < 0.001}. Several pathologic lesions were found significantly more often in the anti-angiogenic preeclampsia group; atherosis {27.7% versus 3.6%, p < 0.05}, infarcts {58.3% versus 3.6%, p = 0.002}, and syncytial knots {81.3% versus 39.3%, p < 0.001}. CONCLUSION: Preeclamptic patients with imbalance in circulating angiogenic factors have disproportionally higher rates of placental vascular lesions historically associated with severe disease.
Authors: Graham W Aberdeen; Jeffery S Babischkin; Jonathan R Lindner; Gerald J Pepe; Eugene D Albrecht Journal: Endocrinology Date: 2022-04-01 Impact factor: 4.736
Authors: Katherine M Johnson; Laura Smith; Anna M Modest; Saira Salahuddin; S A Karumanchi; Sarosh Rana; Brett C Young Journal: Pregnancy Hypertens Date: 2021-05-14 Impact factor: 2.494
Authors: Jesse N Cottrell; Alexis C Witcher; Kyleigh Comley; Mark W Cunningham; Tarek Ibrahim; Denise C Cornelius; Babbette LaMarca; Lorena M Amaral Journal: Am J Physiol Regul Integr Comp Physiol Date: 2021-02-03 Impact factor: 3.210
Authors: Angela Makris; Kristen R Yeung; Shirlene M Lim; Neroli Sunderland; Scott Heffernan; John F Thompson; Jim Iliopoulos; Murray C Killingsworth; Jim Yong; Bei Xu; Robert F Ogle; Ravi Thadhani; S Ananth Karumanchi; Annemarie Hennessy Journal: Hypertension Date: 2016-04-18 Impact factor: 10.190
Authors: Ingrid C Weel; Rebecca N Baergen; Mariana Romão-Veiga; Vera T Borges; Vanessa R Ribeiro; Steven S Witkin; Camila Bannwart-Castro; Jose C Peraçoli; Leandro De Oliveira; Maria T Peraçoli Journal: PLoS One Date: 2016-06-17 Impact factor: 3.240